NEWARK, Calif., June 1, 2026

Protagonist Therapeutics announced that four abstracts featuring rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm, Sweden. The presentations will include new analyses from the randomized Phase 3 VERIFY trial and long-term findings from the Phase 2 REVIVE and THRIVE extension studies, further expanding the clinical evidence supporting rusfertide in patients with phlebotomy-dependent PV.

Phase 3 VERIFY Analyses Highlight Consistent Benefit Across PV Patient Groups

Data from the Phase 3 VERIFY study will evaluate the efficacy and safety of rusfertide in both low-risk and high-risk polycythemia vera patients. Additional analyses will examine the impact of rusfertide on the use of cytoreductive therapies, providing insight into how treatment may help reduce dependence on existing disease-management approaches. These findings are expected to strengthen the understanding of rusfertide’s role in controlling hematocrit levels and reducing the need for frequent phlebotomies.

Long-Term Studies Assess Thromboembolic Risk and Disease Progression

Protagonist will also present long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies. The analysis focuses on thromboembolic events, disease progression outcomes, and long-term safety in patients receiving rusfertide. These data provide an extended view of the therapy’s clinical profile and may offer important evidence regarding the durability of treatment benefits in patients with chronic polycythemia vera.

Advertisement

cGxPJobs Banner

Patient-Reported Outcomes Support Rusfertide’s Clinical Value

Another presentation from the VERIFY study will highlight the effect of rusfertide on PV-related symptoms, fatigue, and patient-reported outcomes. The findings are designed to assess how treatment impacts daily quality of life, an important consideration for patients managing the long-term burden of the disease. Rusfertide, a first-in-class hepcidin mimetic peptide, is currently under FDA priority review and is being co-developed by Protagonist Therapeutics and Takeda Pharmaceutical Company as a potential new treatment option for phlebotomy-dependent polycythemia vera.

Source: Protagonist Therapeutics press release